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To improve the use of N-of-1 studies in rare genetic neurodevelopmental disorders, we sys-
tematically reviewed the literature and formulated recommendations for future studies.
Methods
The systematic review protocol was registered in the PROSPERO International Prospective
Register of Systematic Reviews (CRD42020154720). EMBASE and MEDLINE were searched
for relevant studies. Information was recorded on types of interventions, outcome measures,
validity, strengths, and limitations using standard reporting guidelines and critical appraisal
tools. Qualitative and descriptive analyses were performed.
Results
Twelve studies met the N-of-1 inclusion criteria, including both single trials and series. In-
terventions were mainly directed to neuropsychiatric manifestations. Main strengths were the
use of personalized and clinically relevant outcomes in most studies. Generalizability was
compromised due to limited use of validated and generalizable outcome measures.
Conclusion
N-of-1 studies are sporadically reported in rare genetic neurodevelopmental disorders. Properly
executed N-of-1 studies may provide a powerful alternative to larger randomized controlled
trials in rare disorders and a much needed bridge between practice and science. We provide
recommendations for future N-of-1 studies in rare genetic neurodevelopmental disorders,
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Millions of people worldwide are affected by one of the nearly
8,000 rare disorders, defined as a condition affecting less than
1 in 2,000 individuals according to European definitions.1
Around 80% of these rare disorders are genetic and associated
with neurodevelopmental disorders and/or inborn errors of
metabolism (IEMs).2 Treatment targets are increasingly
identified,3,4 although the lack of evidence now leads to pa-
tients missing out on possibly effective interventions. As
parallel group randomized controlled trials (RCTs) are often
not feasible in these small and heterogeneous populations, a
new methodological framework needs to be developed.
N-of-1 studies are randomized, controlled, multiple crossover
trials in a single patient (figure 1 and table 1)5,6 and closely
follow indications of causality between agent and effect.7,8
Where RCTs generally assess an average treatment effect,
N-of-1 series identify individual particular characteristics that
may modify response to the intervention, addressing the
question of interindividual variability in treatment response.9
Aggregated data of an N-of-1 series can even produce treat-
ment effect estimates at a population level, which may be as
robust as traditional RCTs.10,11 Furthermore, the personal-
ized approach has the potential of maximizing treatment
adherence.5,12–14
Now guidelines on the design and reporting of N-of-1 trials
are available,6,8,15,16 and specific information is needed to
improve N-of-1 studies in patients with rare neuro-
developmental disorders, as these patient populations are
particularly complex, heterogeneous, vulnerable, and under-
studied. Our aim is to (1) provide a systematic review of the
literature on N-of-1 trials in individuals with rare genetic
neurodevelopmental disorders and (2) formulate recom-
mendations to optimize future use and impact.
Methods
We followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis Protocol (figure 2).17 The
methodological framework was published in advance in the
PROSPERO International Prospective Register of Systematic
Reviews (CRD42020154720). Relevant definitions of terms
that were used in this review are provided in the box.
Eligibility
Peer-reviewed studies that used at least 3 controlled episodes
of treatment or comparator (placebo, treatment as usual, no
intervention, an alternative intervention, or other doses of the
same intervention) were included in the review. Genetic
neurodevelopmental disorders were defined as disorders with
a genetic etiology affecting the nervous system in early de-
velopment. IEMs, constituting a subgroup of rare genetic
disorders, were defined as monogenic conditions in which the
impairment of a biochemical pathway is essential to the
pathophysiology of the disorder, typically resulting in either
accumulation of toxic metabolites or shortage of energy and
building blocks for cells. Those presented with intellectual
disability (ID) were considered neurodevelopmental.18,19
Exclusion criteria included idiopathic psychiatric disorders
according to the DSM-5 criteria and genetic etiologies not
confirmed with standard methods. Experts were consulted
to determine whether the phenotypes of Rett syndrome (in
the absence of molecular confirmation) and cerebellar hy-
poplasia tapetoretinal degeneration syndrome were con-
sistent with the tight diagnosis.20,21
Search Strategy, Study Selection, Risk of Bias,
and Quality Assessment
Two separate search strategies were conducted with assis-
tance of a clinical research librarian (J.G.D.) in 2 search
engines: MEDLINE (Ovid), 1946 to November 8, 2019,
and EMBASE (Ovid), 1947 to November 8, 2019. First, the
term N-of-1 and synonyms for all single-case experimental
designs were searched. Second, because few studies ex-
plicitly used this N-of-1 terminology, all rare genetic neu-
rodevelopmental disorders were separately searched in
combination with terms for clinical trials. Specifically, a list
containing all rare genetic and chromosome disorders and
IEMs from the Genetic and Rare Diseases Information
Center of the NIH was used. A time limit for the second
search strategy in EMBASE of the last 10 years was applied
due to the large amount of articles. Additional articles were
identified by scoping search (n = 15), reference list
checking and citation tracking (n = 59), and contacting
authors of relevant articles (n = 6). All searches were
conducted by the librarian and 1 reviewer (A.R.M.).
Rayyan (an application for systematic reviews) was used for
screening.22 All titles and abstracts were screened for rele-
vance by 4 reviewers (A.M.v.E., M.M.M.G.B., E.B., and
A.R.M.) with a subsample of 10% screened for interrater re-
liability. Interrater reliability analysis using the Cohen kappa
statistic was performed to determine consistency between
raters. Full texts were screened against inclusion and exclusion
criteria, and data were independently extracted by at least 2
reviewers, of whom 1 (A.R.M.) covering all studies. Dis-
crepancies were discussed until consensus was reached.
To provide guidance for appraisal of the quality of reporting of
the full text publications and methodology, the Consolidated
Standards of Reporting Trials (CONSORT) extension for
Glossary
ID = intellectual disability; IEM = inborn errors of metabolism; RCT = randomized controlled trial; RoBiNT = Risk of Bias in
N-of-1 Trial.
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reporting N-of-1 Trials (CENT) 20156,23 and the Risk of Bias
in N-of-1 Trials (RoBiNT) Scale15 were scored. The CENT
2015 reporting standard consists of 25 items including rec-
ommendations about what to report and covers optimal
methodology of medical and behavioral sciences. The RoB-
iNT Scale consists of 15 items including subscales on internal
and external validity and evaluates how well a particular
component of a study is conducted. The internal validity scale
of the RoBiNT consists of 7, and the external validity and
interpretation scale of 8 items, with a maximum score of 14
and 16 points, respectively.
Data Extraction
Data were extracted on first author, year of publication,
countries of study, number of participants, diagnosis, patient
characteristics (age, presence/absence of ID, level of ID, Full
Scale Intelligence Quotient, psychiatric diagnosis, comorbid-
ities, and concurrent therapies), selection criteria, institutional
ethical approval, trial design, run-in and washout periods,
number of trial conditions, number and duration of periods,
randomization, blinding, crossover trials, intervention(s), to-
tal intervention duration, comparator used, outcome assess-
ment, major organ system studied, primary/secondary
Table 1 N-of-1 Methodological Terminology
Adherence
The extent to which a patient’s behavior matches agreed recommendations from a health care provider taking into account the
patient’s perspectives.
Block A repeated unit of a set number of periods.
Compliance The extent to which the patient’s behavior corresponds with the prescriber’s recommendations.
Cycle Each repeated unit of a set number of periods within a sequence (e.g., ABA).




Dependent variables in addition to the target behavior used to evaluate transfer effects of the intervention to a broader domain of
functioning including other behaviors or settings.
Internal validity The degree to which the study’s outcomes could be attributed to the intervention being responsible for change in the dependent
variable.
N-of-1 study A prospectively planned randomized, controlled multiple crossover trial to determine the effectiveness of an intervention (A) in a
single participant. Comparators (B) may include placebo, usual care, alternate treatment, or no intervention.
Pair A repeated unit containing only 2 periods.
Period The duration of an intervention, comparator, washout, or run-in.
Suggested inference Interpretation of the extent of generalization of the study’s outcomes to either the individual participants or patients in general
with that specific disorder.
Responsiveness to
change
The ability of an instrument to detect change over time in a construct being measured.
Run-in Time preceding starting treatment at intended dose to avoid sudden introduction of a fixed therapeutic dose to determine
participant compliance or to wash out effects of a previous drug.
Washout Time without an intervention following a treatment period to ensure that effects of treatment have disappeared.
Figure 1 Schematic Presentation of Terminology Used for N-of-1 Trials
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outcomemeasure(s) (presence and type), adverse events, power
analysis, method of primary and/or secondary analysis (quali-
tative, graphical, tabular, (non)parametric statistics, and Bayesian
statistics), main results, suggested inference, and challenges. The
interventions were classified into disease-modifying or symp-
tomatic, using a standard definition of disease-modifying: an
intervention mediating the effect by targeting the primary un-
derlying pathophysiology and changing the course of the disease
with an enduring effect.24 The suggested inference appraised
generalization of the study’s outcomes to either the individual
participants or patients in general with that specific disorder.
Generalization measures were defined as dependent variables in
addition to the target behavior used to evaluate transfer effects of
the intervention to a broader domain of functioning including
other behaviors or settings.15 A generalization measure could be
an assessment of the same behavior in different settings or a
measurement of an interventional effect on a completely
different behavior. These should be identified a priori and mea-
sured throughout all phases. Strengths, limitations, and recom-
mendations noted by the author(s) were collected, and reviewers
were asked for additional comments.
Data Availability
The search strategy and data extraction sheet are available on
request to the first author.
Results
Of 18.483 identified citations, 12 studies met the inclusion cri-
teria, summarized in table 2. One article reported on 2 different
N-of-1 studies with divergent methodological characteristics.25
Study Characteristics
Institutional ethics approval was explicitly mentioned in 8
studies.
Figure 2 PRISMA Flowchart
PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analysis.
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Population
The 12 included studies had an average of 5 participants with
an average age of 21 (range 3–63) years (table 2). Themajority
of the studies (n = 7) did not define the eligibility criteria.
Intervention
Various types of interventions were applied: psychological
therapy (n = 4), dietary supplement (n = 4), drug (n = 3), and
dietary therapy (n = 2; table 2). One study combined 2
subsequent interventions.25 Only some dietary interventions
might be categorized as disease modifying including phenyl-
alanine restriction and folic acid and L-arginine
supplementation,25–28 although distinction was difficult due
to vague demarcations in targeting the possibly underlying
mechanisms. Concurrent therapies were mentioned in 7
studies.
Methodological Characteristics
There was a wide variety of methodological approaches in the
reviewed studies with great variation in number of periods and
trial conditions and duration of the interventional period
(table 3). Only 1 study included a washout period, and 1 study
a run-in. Randomization was applied in 7 studies. None of
those that did randomize explicitly specified the method of
randomization. Seven studies were double blinded, 2 single
blinded, and 4 were not blinded. The main comparator used
















4 11 (9–13) Methylphenidate Child Behavior Checklist, Conners Parent/
Teacher Questionnaire, Side Effects
















6 7 (3–13) Melatonin Average number of hours asleep per 24 h







Down syndrome 5 59 (55–63) Cognitive
stimulation
therapy





6 8 (3–15) Folic acid Vineland Adaptive Behavior Scales, Autistic
Descriptors Checklist, questionnaire about







Phenylketonuria 3 15 (9–21) Phenylalanine
restriction








1 48 L-arginine Quality of life/mood assessment questionnaire,







9 10 (6–22) Ecopipam Behavior Problems Inventory, Clinical Global









2 29 (28–31) Tetrabenazine Global Dystonia rating scale, Fahn-Marsden





Phenylketonuria 6 36 (19–53) Low phenylalanine
diet and behavior
modification





Rett syndrome 3 3 (3–4) Functional
communication
training







10 11 (5–20) Cholesterol—easy
eggs liquid egg
yolks
Aberrant Behavior Checklist (ABC) Caregiver
a Italics when indicated as a primary outcome measure by the authors.
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was placebo followed by no intervention, with some studies ap-
plying a combination of several comparators. Graphical or tabular
analyses were most often used to assess treatment effects. In 4
studies, (non)parametric statistical analyses were performed.
Outcome Measures and Evaluation Methods
In 9 studies, a primary outcome measure was present and
predefined, although only 3 studies explicitly used the term
primary outcome measure. Generally, outcome measures
were targeted at behavioral and cognitive improvements
(table 2). The evaluation methods used were diverse, varying
from validated questionnaires to self-designed scoring lists.
Only in myoclonus-dystonia syndrome, condition-specific
rating scales were used.29 Once, a quality of life assessment
was used.28 In 4 studies, biological plasmameasurements were
assessed to confirm an appropriate blood level of either the
supplement or diet. None of the studies included general-
ization measures. Mostly, outcomes were assessed by care-
givers and to a lesser degree by investigators.
Main Results and Adverse Events
Neither the supplement nor diet interventions revealed signifi-
cant positive results, whereas results of drug interventions varied
and nondrug interventional studies all reported positive effects,
though not substantiated with statistical analysis. One study had
to be prematurely discontinued due to unexpected adverse
events to the study drug (ecopipam)30; the authors concluded
that a run-in period would probably have prevented this.
Suggested Inferences
In 9 studies, results were interpreted as generalizable to all pa-
tients with the same condition, whereas the authors of 2 studies
considered the experiment as evidence for the individual par-
ticipant only. One study did not report on inference.
Quality Assessment and Risk of Bias
Internal Validity
Themedian of the internal validity score of the included N-of-
1 studies as assessed by the RoBiNT was 6.5 of 14 points









duration Randomization Blinding Comparator(s) Type of analyses
Bawden ABAB/ABBA/BAAB 5 1 wk 5 wks Yes Double
blind
Placebo Tabular







Camfield ABABABABAB 10 1 wk 10 wks Yes Double
blind
Placebo Tabular
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(range 3–11; figure 3A). Treatment adherence was not
assessed with the exception of 1 study that scored the maxi-
mum on treatment adherence by fulfilling the requirements of
using a clear rating system, an independent assessor of the
participant and sampling of more than 20% of the data,
resulting in a minimum of 80% adherence.20 The interrater
agreement was adequately evaluated in 3 studies with separate
reporting on the dependent variables for each condition.
External Validity and Interpretation
Themedian of the external validity score of the includedN-of-
1 studies was 9 of 16 points (range 4–11; figure 3B). The
dependent variable (target behavior) was in 8 of 12 studies
operationally defined with description of the measuring
method. The other 4 studies did define the target behavior,
but without clear and precise description of methods of
measuring. Also, studies scored relatively high on describing
practical matters including equipment, manuals, and pro-
cedural details. Although 1 study described the intervention in
vague or general terms, 6 studies provided broad but not
detailed descriptions of the content of the intervention or
lacked one of the procedural’s items including the number,
duration, and frequency of periods for each participant. The
other 5 studies provided a detailed description of the content
of the intervention, the procedure of delivery, and any
equipment and manuals used. However, low scores were
found on description of baseline characteristics (9/24 points),
data analysis (8/24 points), and generalization (0/24 points),
referring to the inclusion of generalization measures.
Reporting of the N-of-1 Trials Against CENT 2015
Criteria
None of the studies provided a registration number, name of trial
registry, nor information about accessibility of the full trial pro-
tocol. Two studies identified the study as (a series of) N-of-1
trials in the title.21,28 The rationale for using an N-of-1 approach
was not clarified in any of the studies. Other omissions included
the description and measurement properties including validity
and reliability of outcome assessment tools, determination of
sample size or requirement of the number of periods in a single
N-of-1 study, and randomization and sequence allocation with a
rationale or method. Carryover effects were not addressed, nor
were period effects. As for the series, quantitative synthesis of
individual data, including subgroup and sensitivity analyses, ad-
justed analyses, and analyses to determine heterogeneity be-
tween participants, were not reported. Moreover, (group)
estimated effect sizes and its precision for each primary and
secondary outcome were only reported in 2 studies.27,31
Figure 3 Schematic Representation of the Risk of Bias in N-of-1 Trials (RoBiNT) Scale
(A) Items of internal validity. (B) Items
on external validity and interpretation.
The y-axis indicates the included N-of-
1 studies ordered per first authors.
Circles indicate scores on the 3-point
rating scale where 2 points were
awarded for meeting the recom-
mended stringent criteria (green), 1
point to otherwise defined criteria
(yellow), and 0 points for not meeting
the stringent criteria of the design
standards (red).
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Strengths of the N-of-1 Studies Identified
The main strengths reported by the studies’ authors included
individual-centered evidence-based interventions and the in-
tent to measure personalized and clinically relevant outcomes.
Other assets were independence of assessors, control for day-
to-day variation in symptoms, and use of subjective as well as
objective and biological measures of treatment. Reviewers
identified additional strengths that were encountered in some
but not all studies: proof of concept in relatively small studies,
individual-centered, multiple assessors, inclusion of baseline
conditions, (clinically) relevant outcome measures, inclusion
of control participants to determine whether effect is specific
to the genetic disorder, and the systematic approach.
Limitations of the N-of-1 Studies Identified
The authors of the conducted N-of-1 studies reported diffi-
culty with identifying appropriate and validated outcome
measures, especially for specific genetic heterogeneous con-
ditions for which outcome measures were often subjective.
Reviewers additionally identified unclear measurement
properties as a limitation, involving reliability, validity, and
responsiveness. Psychological interventions and outcome
assessment were vulnerable to bias because of subjectivity,
task engagement, and personal attention or interaction. In 1
study, indications for a strong negative caretaker bias of a
seemingly already proven intervention based on anecdotal
reports of efficacy and prejudices were reported to have
Figure 4 Challenges and Recommendations for Conducting and Reporting N-of-1 Studies in Rare Genetic Neuro-
developmental Disorders
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affected recruitment of participants, compliance, and, sub-
sequently, outcome scores.31 Also, a difference between ratings
by caregivers and research personnel was perceived in some
studies without assessing an interrater agreement. Finally, dif-
ficulty with statistical analysis was identified. As N-of-1 studies
could have different purposes such as a proof of concept,
providing an individual treatment decision, or estimating the
treatment effect at a population level, the level of complexity
and necessity of statistical analyses might be contingent on the
reason for the study. Specifically, the degree of certainty desired
was taken into consideration by the author(s) in 1 study where
a visual analysis clearly showed that the active intervention was
beneficial compared with placebo, but the statistical analyses
did not reveal significant results in some cases.28
Discussion
N-of-1 studies have been recommended for evaluating the effi-
cacy of interventions in rare disorders.32,33 However, in this
extensive review, only 12 studies complied with the fundamental
N-of-1 criteria of a controlled multiple crossover trial, showing
limited use and reporting of N-of-1 trials for rare genetic neu-
rodevelopmental disorders. In addition to limitations in design
and statistical analysis, generalizability and feasibility were par-
ticularly challenging. Below, limitations are discussed and rec-
ommendations are provided to implement and optimize future
N-of-1 studies in this patient population (figure 4).
Although the genetic disorder and presence of ID were generally
reported, diagnostic and eligibility criteria, comorbid conditions,
and concurrent therapies were often unclear. Rare genetic neu-
rodevelopmental disorders are often accompanied by various and
often variable levels of ID and severe comorbidities. This intra-
and interindividual heterogeneity can complicate generalization
of findings to other patient populations. To optimize in-
terpretation and generalizability, eligibility criteria and baseline
characteristics pertaining to the study population as well as en-
vironment should be thoroughly described.
The rationale for the intervention was well described in the
reported studies. Distinction between disorder-specific and
disease-modifying drugs was not performed by the authors.
Categorization was difficult for some included studies as in-
terventions may be disorder specific and not directly change
its natural course by for example not targeting the primary
underlying pathophysiology as exemplified by the study to L-
arginine supplementation in ornithine transcarbamylase de-
ficiency.28 Despite the fact that L-arginine supplementation
does not target ornithine transcarbamylase itself but rather the
consequences of the enzymatic deficiency, L-arginine ame-
liorates the overall function of the urea cycle by maintaining a
normal rate of protein synthesis.28
To optimize impact of N-of-1 studies, it is important to specify
whether a trial will focus on syndrome-specific or more com-
mon manifestations. Now that disease-modifying drugs are
becoming increasingly available,18 consideration of disorder-
specific effects is especially important with regard to general-
izability to other patient populations. Also, disease-modifying
drugs may have age- or comorbidity-dependent effects. For
example, therapeutic effects of mammalian target of rapamycin
inhibitors for tuberous sclerosis complexmight differ over time,
across patients, and across manifestations.34,35 This emphasizes
the need for detailed baseline characteristics.
The interventions of the included studies were mainly directed
to neurobehavioral manifestations such as improving cognition,
behavior, and quality of life, underlining the great burden of
neuropsychiatric symptoms for patients as well as caregivers in
patients with rare genetic neurodevelopmental disorders.36
Considering the high burden of shared neuropsychiatric
comorbidity, symptomatic interventions are of pivotal impor-
tance as their effect may be disorder transcending. Hence, es-
pecially symptomatic drug and nondrug trials should discuss
generalizability of their intervention to other populations,
taking disorder-specific effects and side effects into account.
The critical need for well-controlled studies before interven-
tions becomes established as standard of care was underscored
by a negative caretaker bias encountered in 1 study.31
Only 2 studies were explicitly identified by the authors as an
N-of-1 trial, underlining the need of a common terminology.
The rationale for the N-of-1 design was generally not speci-
fied. Other limitations regarding the trial design were ob-
served including unclear justification of trial and intervention
duration, lack of run-in periods, carryover effects, randomi-
zation, and blinding.
It has been proposed that conditions should be stable over time
to be eligible for conducting an N-of-1 study.37 IEMs are
however typically (neuro)degenerative disorders resulting in an
unstable and often variable natural course across patients. As
the natural history of other types of neurodevelopmental dis-
orders unfolds, this variable course increasingly applies tomany
other genetic neurodevelopmental disorders.38,39 However,
even for unstable manifestations, effects may be observed by
tracing the overall enduring effect on the personal course, in-
cluding (multiple) baseline, placebo, and follow-up measure-
ments. In this way, disease-modifying treatment options can be
investigated, theoretically expecting a more enduring effect on
the individual’s natural course for disease-modifying drugs vs a
temporary effect for symptomatic drug treatments.
To substantiate the duration of the interventional period, phar-
macokinetics and dosage should be taken into full consideration.
Dosage should be based on factors such as half-life time, age,
weight, and daily timing. Both low dosages and high dosages
without a run-in period can result in dropout and lack of
efficacy.21,30 Multiple dosages might be considered by imple-
menting anABCdesign or adjusting dosages after interim analyses.
To minimize carryover and side effects, addition of a run-in
and/or washout period is preferred.40,41 In addition to
Neurology.org/N Neurology | Volume 96, Number 11 | March 16, 2021 537
biological carryover effects based on half-life time of drugs,
psychological carryover effects for the patient as well as
proxies should be considered, such as relief of parental stress
after a period with an effective intervention. A baseline con-
dition to observe natural behavior without any intervention
and a follow-up will add internal validity and information
about the effectiveness and tolerability of an intervention.
To gauge the robustness of methods chosen for randomization
and sequence allocation, this should be thoroughly described,
such as steps taken to conceal the sequence, information about
who generated the sequence, who enrolled participants, and
who assigned them to interventions. Various randomization
and implementation methods may be appropriate depending
on the condition and design.40 Interpretation of observed ef-
fects becomes problematic with randomization when outcomes
unexpectedly or progressively deteriorate or improve.6 Coun-
terbalancing can be used to systematically alternate the treat-
ment order (such as ABBA instead of AABA or AABB) so that
neither treatment suffers a worse fate than the other.42
In terms of personalized care, included studies were com-
mendable by tailoring interventions to patient or caregiver
needs, thus ensuring relevance and optimizing treatment ad-
herence. Outcome measures included objective and biological
outcomes, validated symptom checklists, neuropsychological
assessments, or personalized outcomes. Preferably, all types are
included to optimize pathophysiologic insights as well as rele-
vance to the patient. Feasibility of N-of-1 studies in these vul-
nerable patients was questioned in 4 studies. As anN-of-1 study
might be time and effort consuming for several stakeholders
involved in the study because of frequent recording of data
points enabling multiple measurements, and the number of
periods and duration of the trial, increasing treatment adher-
ence should be prioritized. To foster treatment and trial ad-
herence, patient involvement on the intervention, design, and
outcome measures appears to greatly contribute to the expe-
rienced relevancy and enthusiasm of participants.43 However,
this might strengthen potential placebo effects. As participants
with ID can often not report on their clinical condition, this
places a demand on parents and caregivers. Proxy-friendly as-
sessment tools are required to ensure trial compliance.
Targeting behavioral outcomes in patients with rare disorders
and varying levels of cognitive functioning is complex as ap-
propriate outcome measures are limited and often lack val-
idity.44 Hence, interpretation of efficacy is hampered leading to
disappointing results of disorder-specific interventional studies.
This underlines the need for more sensitive and disorder-
specific evaluation strategies, such as the phenylketonuria–
quality of life (PKU-QOL) questionnaire.45 For outcomes, the
property responsiveness to change is essential in measuring
the effectiveness of interventions but is often unknown. Of the
included studies that used existing rating scales, responsiveness
to change was discussed for Dementia Care Mapping, the
Vineland Adaptive Behavior Scale, and the Behavior Problems
Inventory.46–48 Of interest to heterogeneous populations with
ID is the recently introduced NIH battery of neuro-
psychological assessments, which is increasingly validated.49
As patients with rare genetic neurodevelopmental disorders
comprise a vulnerable patient group often affected by severe
comorbidity and complex environmental factors, there is a
great need for personalized and disorder-specific outcome
measures. This was also indicated by the frequent use of self-
designed outcome measures in the included studies. Instru-
ments such as patient-reported outcome measures,44,50 Goal
Attainment Scaling,51 or experience-sampling methods52 may
be considered, enabling quantitative expression of meaningful
subjective patient experiences while translating these into
evidence.43 As personalized outcome measures may com-
promise generalizability, inclusion of generalization measures
can provide information on transfer effects of the intervention
to other behaviors, settings, or disorders that may be either
closely or distally related to the target behavior.15
One main shared shortcoming was the lack of statistical
analyses. None of the 12 studies included a justification for the
sample size. Sample size calculations are important to ensure
that clinically relevant effects can be detected while not in-
cluding, and hence burdening, too many patients. In N-of-1
trials, a power analysis can help decide on the number of
periods required to detect a clinically relevant treatment effect
within a patient and, in case of a series of N-of-1 trials, for the
number of participants required to determine an average
treatment effect in the study sample. Formulas and methods
for calculation of the required sample size for these different
objectives are available for N-of-1 studies.53
The majority of the studies only described results using
graphical or tabular methods, whereas (non)parametric sta-
tistical analyses are now considered the standard for testing
for an intervention effect in N-of-1 studies.54 (Non)para-
metric and ancillary analyses should be performed to evaluate
period effects, intrasubject correlations, and subgroup and
adjusted effects. Rather than attempting to adjust for carry-
over effects, it is preferred to choose the (washout) periods
long enough for carryover not to occur.
Both mixed-effects models and Bayesian models can properly
address the inter- and intrapatient variability in series of N-of-
1 trials.41 A clear overview is given of the various frequentist
analyses proposed for N-of-1 trials that may serve different
purposes.40 Most importantly, the statistical methods should
properly account for the method of randomization used.
Simple analyses such as a paired t test and a summary measure
approach can be acceptable for testing the hypothesis of a
difference between treatments. For assessing heterogeneity of
the treatment effects between individuals, a mixed model
approach is required40 with an ANOVA type test for hy-
pothesis testing. The latter can also be done in a Bayesian
framework using hierarchical modeling. In a Bayesian
framework, it is quite natural to update an estimation when
data from new N-of-1 trials become available. If one wishes to
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produce shrunken estimates or predict the effects for future
patients, a hierarchical Bayesian model or linear mixed model
with random treatment-by-patient interaction is required.
Reporting an N-of-1 trial should satisfy particular N-of-1
items according to CENT 2015 and RoBiNT15,23 (figure
4). Because of the differences in N-of-1 terminology that
still exist, studies should identify the trial as an N-of-1 in
both the title and the abstract. In addition to the items
discussed above and in Figure 4, a rationale for using the
N-of-1 design should be provided because N-of-1 trials may
serve a number of different purposes53 and several single-
case experimental designs could be considered.32 More
specifically, we especially recommend an N-of-1 study in
rare genetic disorders when the intervention has a pre-
dictable duration of effect for which a valid off-period is
possible and low recruitment rates are expected. Finally,
trial registration and an accessible full trial protocol in-
cluding specific methodological choices might be of pivotal
importance for future N-of-1 studies. In line with recent
guidelines for N-of-1 trial protocols and reporting,6,8 we
recommend facilitation of entry of N-of-1 studies into
primary registries within the World Health Organization’s
International Trials Registry Network and clinicaltrials.gov.
A strength of this study is the comprehensive search strategy
necessitated by the historical lack of uniformity in N-of-1 ter-
minology. The large amount of records identified through this
search inadvertently may have resulted in inappropriate ex-
clusions. N-of-1 studies that were directed toward symptoms
solely without mentioning underlying disorders might also
have been missed as our search was developed with a gene first
approach. Of note, the recommendations reflect the authors’
opinions rather than a systematically derived consensus.
N-of-1 studies have great potential to provide evidence of
effectiveness for individuals as well as groups of patients. The
findings of this review show only limited use of N-of-1 studies
in rare genetic neurodevelopmental disorders and that im-
provement of methodology is essential to provide a suitable
alternative for RCTs. We provide recommendations to en-
hance methodological and statistical quality as well as gen-
eralizability, feasibility, and personalization. Future use of this
N-of-1 framework will assist in realizing the sorely needed
evidence-based interventions for these vulnerable patients.
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